Yale University spinoff · Branford, Connecticut

The message is in the blood.

Wren Laboratories harnesses breakthrough mRNA liquid biopsy to transform cancer care and accelerate drug development — a functional, real-time view of tumor biology from a simple blood draw.

Order a test Explore our tests

CLIA · CAP · NYSDOH · ISO 15189NETest 2.0® · 51 genesPROSTest® · 27 + 3 genes

Deeper cancer insights

Mutations are the script. mRNA is the performance.

While next-generation sequencing identifies gene alterations, not all mutations result in functional consequences. mRNA carries the gene’s instructions — mutated or not — into biological action.

Wren’s proprietary RNA stabilization and testing platform detects aberrations in signaling pathways, the drivers of tumor behavior — actionable insight for cancer care providers and drug development teams.

Our technology

DNA

01 · Genome

What could go wrong

Sequencing reveals gene alterations — but a mutation alone doesn’t tell you whether it is driving disease.

mRNA

02 · Transcriptome

What is going wrong — now

mRNA links genome abnormalities with disease behavior. Measured from whole blood across multi-gene panels, it captures the tumor’s live activity.

PROT

03 · Phenotype

Growth, evasion, spread

Those instructions drive protein production — and with it the cancer’s ability to grow and evade control.

Clinical excellence

Evidence built with 45 institutions in 16 countries.

115+Patents

51+Peer-reviewed publications

60+Clinical studies

45+Collaborating medical institutions

70+Investigators worldwide

10000+Patients tested

Meet our collaborators

Validated assays

Two tests. One tube of blood.

Our NETest 2.0® and PROSTest® provide clinically validated multi-gene mRNA diagnostics for neuroendocrine tumors and prostate cancer — for diagnosis, prognosis, monitoring and therapy-response prediction.

Neuroendocrine tumorsBlood · RT-PCR · ML

NETest 2.0^®

A 51-gene blood test for neuroendocrine tumors, analytically validated and demonstrated in over 50 third-party studies.

51cancer-associated genes

94%analytical accuracy

1cell/mL-RNA equivalent sensitivity

94%Diagnosis. 94% of patients with a high diagnostic score are likely to have a NET; 90% with a low score do not.
80%Prognosis. High scores: 80% chance of tumor progression; low scores: 90% chance of stable disease.
84%Monitoring. Rising serial diagnostic scores detect MRD or recurrence in 84% of cases.
95%PRRT response. PPQ-positive: 95% likelihood of benefit from PRRT, vs 10% of PPQ-negative patients.

PROGNOSTIC SCORE0 — 100

NETest 2.0® details

Prostate cancerBlood · RT-PCR · ML

PROSTest^®

A machine-learning liquid biopsy analyzing 27 cancer-associated genes and 3 reference genes from 1 mL of blood.

27+3target + reference genes

93%analytical accuracy

2cells/mL-RNA equivalent sensitivity

93%Diagnosis. High score: 93% likelihood of prostate cancer; low score: 90% chance of no disease.
93%Monitoring. Rising serial scores detect MRD or recurrence in 93% of cases.
90%Drug efficacy. Falling serial scores indicate drug efficacy in 90% of cases.
↑Prognosis. Elevated scores correlate with shorter overall survival.

PROSTEST SCORE0 — 100

PROSTest® details

Interactive

From a 0–100 score to a clinical answer.

Every Wren test turns multi-gene mRNA expression into a machine-learning score, read against a clinically validated cutoff. Drag the dial, tap a preset, or press Sweep to watch the interpretation change at the cutoff.

NETest 2.0® diagnostic — cutoff 50, likelihood of NET disease
NETest 2.0® prognostic — cutoff 40, risk of progression or recurrence
NETest PPQ® — cutoff 50, predicted PRRT responder
PROSTest® — cutoff 50, prostate cancer positive vs negative

Educational illustration of published cutoffs. Not a diagnostic tool — results are interpreted by the ordering physician.

NETest 2.0® diagnostic score

Interactive

DRAG THE DIAL · ARROW KEYS · OR TAP A PRESET

Interpretation as printed on Wren’s NETest 2.0 report: scores <50 low likelihood of NET disease; 50–100 high likelihood of NET.

Who we serve

Built for every link in the chain.

01 · Providers

Order with confidence

Real-time, non-invasive mRNA diagnostics for personalized treatment plans and patient monitoring.

For providers 02 · Patients

Champion personalized care

Essential information that patients and their oncologists need to know about our neuroendocrine and prostate cancer tests.

Patient information 03 · BioPharma & Research

Accelerate precision drug discovery

From discovery to companion diagnostic development — with bioinformatics, quality-system and regulatory support.

Partner with us

How it works

From vein to verdict in five steps.

Kits ship to your office, samples travel at ambient temperature, and results come back to the ordering physician.

Submit an order

Through our provider portal or the requisition form.

Receive a kit

Shipped to your office — or the patient’s home for mobile phlebotomy.

Return the sample

Ambient shipping with 10-day RNA stability. No dry ice.

RNA analysis

mRNA isolated and quantified by RT-PCR, scored 0–100 by validated algorithms.

Get results

Reported directly to the ordering physician.

Pipeline

More cancers. Same platform.

Beyond neuroendocrine and prostate cancer, Wren is developing blood-based tests for colorectal, pancreatic, lung, breast, melanoma and multiple myeloma — and for endometriosis.

TESTSTAGE REACHEDDEVRUOCLINICALCLIA/NYSFDA

NETest — Blood

Available · NYS approved

PROSTest — Blood

Available · NYS approved

COLOcheck — Blood

Exploratory clinical study

Multiple myeloma — Blood

Exploratory clinical study

Pancreatic — Blood

RUO

Melanoma — Blood

RUO

Breast — Blood

RUO

Lung — Blood

RUO

Endometriosis — Blood

RUO

See the full pipeline

Our laboratory

Precision medicine, made in Branford.

Wren Laboratories, a Yale University spinoff and CLIA, CAP, NYSDOH and ISO 15189-certified lab, is committed to advancing precision medicine through cutting-edge mRNA diagnostics, improving cancer care, and accelerating drug development.

MISSION